Study of Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant


Study Number
2086021
Phase
II/III
Age Group
Adult
Pediatric
Purpose

This is a Phase 3 study to evaluate posoleucel (ALVR105, formerly Viralym-M); an allogeneic, off-the-shelf multi-virus specific T cell therapy that targets six viral pathogens: BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6 and JC virus.

Full Title

Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to assess the safety and efficacy of ALVR105 (Viralym-M) Compared to Placebo for the prevention of AdV, BKV, CMV, EBV, HHV-6, and JCV Infection and/or disease, in High-risk…

ClinicalTrials.Gov ID
NCT05305040

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.